Circulating microRNA changes in patients with impaired glucose regulation

References

• Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. 2000;23:1108–1112.
   PubMed Web of Science ®Google Scholar
• Karolina DS, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012;97:E2271–6.
   PubMed Web of Science ®Google Scholar
• Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48:61–69.
   PubMed Web of Science ®Google Scholar
• Mononen N, Lyytikäinen L-P, Seppälä I, et al. Whole blood microRNA levels associate with glycemic status and correlate with target mRNAs in pathways important to type 2 diabetes. Sci. Rep. 2019;9.
   Web of Science ®Google Scholar
• Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17:118–126.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–10518.
   PubMed Web of Science ®Google Scholar
• Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–653.
   PubMed Web of Science ®Google Scholar
• Hennessy E, O’Driscoll L. Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Rev Mol Med. 2008;10:1–20.
   Google Scholar
• Pordzik J, Jakubik D, Jarosz-Popek J, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18:113.
   PubMed Web of Science ®Google Scholar
• Jiménez-Lucena R, Camargo A, Alcalá-Diaz JF, et al. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Experimental & Molecular Medicine. 2018;50:1–12.
   PubMed Web of Science ®Google Scholar
• De Rosa S, Arcidiacono B, Chiefari E, et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2.
   PubMed Web of Science ®Google Scholar
• Ofstad AP. Myocardial dysfunction and cardiovascular disease in type 2 diabetes. Scand J Clin Lab Invest. 2016;76:271–281.
   PubMed Web of Science ®Google Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biology. 2011;13:423–433.
   PubMed Web of Science ®Google Scholar
• Michell DL, Vickers KC. Lipoprotein carriers of microRNAs. Biochim Biophys Acta - Mol Cell Biol Lipids. 2016;1861:2069–2074.
   PubMed Web of Science ®Google Scholar
• Song J, Yoon SR, Kim OY. MiR-Let7A controls the cell death and tight junction density of brain endothelial cells under high glucose condition. Oxid Med Cell Longev. 2017;2017. DOI:10.1155/2017/6051874
   Web of Science ®Google Scholar
• Mononen N, Lyytikäinen LP, Seppälä I, et al. Whole blood microRNA levels associate with glycemic status and correlate with target mRNAs in pathways important to type 2 diabetes. Sci Rep. 2019;9.
   Web of Science ®Google Scholar
• Demirsoy İH, Ertural DY, Balci Ş, et al. Profiles of circulating MiRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem. 2018;37:499–506.
   PubMed Web of Science ®Google Scholar
• Karolina DS, Armugam A, Tavintharan S, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011;6. DOI:10.1371/annotation/698b7123-174f-4a09-95c9-fd6f5017d622
   PubMed Web of Science ®Google Scholar
• Bhatwadekar AD, Yan Y, Stepps V, et al. MiR-92a corrects CD34+ cell dysfunction in diabetes by modulating core circadian genes involved in progenitor differentiation. Diabetes. 2015;64:4226–4237.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wen L, Martin M, et al. Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of MicroRNA-92a. Circulation. 2015;131:805–814.
   PubMed Web of Science ®Google Scholar
• Jansen F, Wang H, Przybilla D, et al. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus. Cardiovasc Diabetol. 2016;15:49.
   PubMed Web of Science ®Google Scholar
• Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc (2003). 2009;49(Suppl 1)S3–9.
   Google Scholar
• Fung EC, Butt AN, Eastwood J, et al. Circulating microRNA in cardiovascular disease. In: Advances in clinical chemistry. Vol. 91, Academic Press Inc.; 2019. p. 99–122. ISBN 9780128174715.
   Google Scholar
• Arner P, Andersson DP, Bäckdahl J, et al. Clinical and translational report cell metabolism clinical and translational report weight gain and impaired glucose metabolism in women are predicted by inefficient subcutaneous fat cell lipolysis. Cell Metab. 2018;28:45–54.
   PubMed Web of Science ®Google Scholar
• Malipatil N, Fachim HA, Siddals K, et al. Data independent acquisition mass spectrometry can identify circulating proteins that predict future weight loss with a diet and exercise programme. J Clin Med. 2019;8:141.
   Web of Science ®Google Scholar
• Song J, Lee JE. ASK1 modulates the expression of microRNA Let7A in microglia under high glucose in vitro condition. Front Cell Neurosci. 2015;9. DOI:10.3389/fncel.2015.00198
   Web of Science ®Google Scholar
• Shi W, Zhang Z, Yang B, et al. Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma. Med (United States). 2017;96:e7764.
   Google Scholar
• Li Z, Pan W, Shen Y, et al. IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. Cell Cycle. 2018;17:1212–1219.
   PubMed Web of Science ®Google Scholar
• Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114:434–443.
   PubMed Web of Science ®Google Scholar
• Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–622.
   PubMed Web of Science ®Google Scholar
• Davoren PA, McNeill RE, Lowery AJ, et al. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008;9. DOI:10.1186/1471-2199-9-76
   PubMed Web of Science ®Google Scholar
• Rinnerthaler G, Hackl H, Gampenrieder SP, et al. miR-16-5p is a stably-expressed housekeeping MicroRNA in breast cancer tissues from primary tumors and from metastatic sites. Int. J. Mol. Sci. 2016;17:156.
   PubMed Web of Science ®Google Scholar
• White Paper. A technical guide to identifying miRNA normalizers using TaqMan advanced miRNA assays. [cited 2020 Apr 1]. Available from: https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FGSD%2FReference-Materials%2Fidentifying-mirna-normalizers-white-paper.pdf&title=V2hpdGUgUGFwZXI6IEEgdGVjaG5pY2FsIGd1aWRlIHRvIGlkZW50aWZ5aW5nIG1pUk5BIG5vcm1hbGl6ZXJzIHVzaW5nIFRhcU1hbiBBZHZhbmNlZCBtaVJOQSBBc3NheXM=.
   Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101–1108.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Julian GS, de Oliveira RW, Perry JC, et al. Validation of housekeeping genes in the brains of rats submitted to chronic intermittent hypoxia, a sleep apnea model. PLoS One. 2014;9:e109902.
   PubMed Web of Science ®Google Scholar
• Walder RY, Wattiez A-S, White SR, et al. Validation of four reference genes for quantitative mRNA expression studies in a rat model of inflammatory injury. Mol Pain. 2014;10:55.
   PubMed Web of Science ®Google Scholar
• Gevaert AB, Witvrouwen I, Vrints CJ, et al. MicroRNA profiling in plasma samples using qPCR arrays: recommendations for correct analysis and interpretation. Plos One. 2018;13:e0193173.
   PubMed Web of Science ®Google Scholar
• Fachim HA, Siddals K, Malipatil N, et al. Lifestyle intervention in individuals with impaired glucose regulation affects Caveolin-1 expression and DNA methylation. Adipocyte. 2020;9:96–107.
   PubMed Web of Science ®Google Scholar
• Su J-L, Chen P-S, Johansson G, et al. Function and regulation of Let-7 family microRNAs. MicroRNA E. 2012;1:34–39.
   PubMedGoogle Scholar
• Boyerinas B, Park SM, Hau A, et al. The role of let-7 in cell differentiation and cancer. Endocrine-Related Cancer. 2010;17:F19-F36.
   PubMed Web of Science ®Google Scholar
• Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in Mice. Science. 2009;324:1710–1713.
   PubMed Web of Science ®Google Scholar
• Hourigan ST, Solly EL, Nankivell VA, et al. The regulation of miRNAs by reconstituted high-density lipoproteins in diabetes-impaired angiogenesis. Sci Rep. 2018;8. DOI:10.1038/s41598-018-32016-x.
   PubMed Web of Science ®Google Scholar
• Wang X, Zheng Y, Ma Y, et al. Lipid metabolism disorder induced by up-regulation of miR-125b and miR-144 following β-diketone antibiotic exposure to F0-zebrafish (Danio rerio). Ecotoxicol Environ Saf. 2018;164:243–252.
   PubMed Web of Science ®Google Scholar
• Ma W, Kang Y, Ning L, et al. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Exp Ther Med. 2017;14:2853–2862.
   PubMed Web of Science ®Google Scholar
• Poloznikov AA, Nikulin SV, Raigorodskaya MP, et al. Changes in the metastatic properties of MDA-MB-231 cells after IGFBP6 gene knockdown is associated with increased expression of miRNA genes controlling INSR, IGF1R, and CCND1 genes. Bull Exp Biol Med. 2019;166:641–645.
   PubMed Web of Science ®Google Scholar
• Jones A, Danielson KM, Benton MC, et al. miRNA signatures of insulin resistance in obesity. Obesity. 2017;25:1734–1744.
   PubMed Web of Science ®Google Scholar
• Narayanan R, Fu B, Payton A, et al. IGF2 gene polymorphisms and IGF-II concentration are determinants of longitudinal weight trends in Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013;121:361–367.
   PubMed Web of Science ®Google Scholar
• Minchenko DO, Tsymbal DO, Davydov VV, et al. Expression of genes encoding IGF1, IGF2, and IGFBPs in blood of obese adolescents with insulin resistance. Endocr Regul. 2019;53:34–45.
   PubMedGoogle Scholar
• Kammel A, Saussenthaler S, Jähnert M, et al. Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice. Hum Mol Genet. 2016;25:2588–2599.
   PubMed Web of Science ®Google Scholar
• Biernacka KM, Uzoh CC, Zeng L, et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. 2013;20:741–751.
   PubMed Web of Science ®Google Scholar
• Lu P, Zhao Z. Advances on PPARγ research in the emerging era of precision medicine. Curr Drug Targets. 2018;19:663–673.
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41:425–443.
   PubMed Web of Science ®Google Scholar
• Baxter RC, Twigg SM. Actions of IGF binding proteins and related proteins in adipose tissue. Trends Endocrinol Metab. 2009;20:499–505.
   PubMed Web of Science ®Google Scholar
• Slaaby R, Schäffer L, Lautrup-Larsen I, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem. 2006;281:25869–25874.
   PubMed Web of Science ®Google Scholar